Does semaglutide (Ozempic/Wegovy) cause disproportionate muscle loss compared to standard weight loss?

Clinical data from studies on semaglutide, such as the STEP trials, indicate that while lean mass loss can occur, there is no evidence to suggest that semaglutide causes disproportionate muscle wasting compared to other weight loss approaches. Research findings show that the decrease in lean mass with semaglutide is not significantly different from that seen with equivalent weight loss achieved through different methods. Additionally, muscle function may be maintained despite some loss in muscle volume. Strategies such as protein intake and resistance training are recommended to prevent muscle loss while on GLP-1 medications.

Key Findings

Clinical data from studies on semaglutide, such as the STEP trials, indicate that while lean mass loss can occur, there is no evidence to suggest that semaglutide causes disproportionate muscle wasting compared to other weight loss approaches. Research findings show that the decrease in lean mass with semaglutide is not significantly different from that seen with equivalent weight loss achieved through different methods. Additionally, muscle function may be maintained despite some loss in muscle volume. Strategies such as protein intake and resistance training are recommended to prevent muscle loss while on GLP-1 medications.

Supporting Evidence

• A systematic review found no significant change in physical function despite decreased muscle volume in patients receiving semaglutide.
• Expert opinion suggests that studies do not show disproportionate muscle loss with GLP-1 medications like semaglutide.
• Research indicates that the weight lost on semaglutide does not disproportionately come from muscle compared to other tissues.

Limitations and Caveats

• Some studies highlight that a portion of weight lost on semaglutide can come from lean mass, emphasizing the importance of strategies to prevent muscle loss.
• Concerns about muscle loss may be more pronounced in older adults compared to younger populations.

Practical Implications

• Patients using semaglutide should consider incorporating protein-rich foods and resistance training into their weight loss regimen to help preserve muscle mass.
• Monitoring body composition changes and adjusting lifestyle factors can help mitigate potential muscle loss while on GLP-1 medications.

• Studies indicate that muscle function may be maintained despite some loss in muscle volume in patients receiving semaglutide.
• Expert opinion suggests that studies do not show disproportionate muscle loss with GLP-1 medications like semaglutide.
• The weight lost on semaglutide does not disproportionately come from muscle compared to other tissues.